Advertisement

Topics

ProtoKinetix Enters into 3rd Phase of Retinal Cell Replacement Therapy Testing at UBC

15:55 EDT 10 Aug 2018 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB:PKTX) has entered into the 3rd phase of testing in retinal cell replacement therapy at the University of British Columbia. Due to...

Other Sources for this Article

ProtoKinetix, Incorporated
Clarence E. Smith, 304-299-5070
President and Chief Executive Officer
Email: csmith@protokinetix.com
Twitter: @ProtoKinetix

NEXT ARTICLE

More From BioPortfolio on "ProtoKinetix Enters into 3rd Phase of Retinal Cell Replacement Therapy Testing at UBC"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Transplantation
Organ transplantation is the moving of an organ from one body to another or from a donor site to another location on the patient's own body, for the purpose of replacing the recipient's damaged or absent organ. The emerging field of regenerative ...